Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL551616 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783375 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL705594 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL4165739 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 43778 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-3810091-B1 | COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | ABRAXIS BIOSCIENCE LLC (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099311-A2 | MICROBIAL CELL FACTORIES PRODUCING PROSTAGLANDINS | RIVER STONE BIOTECH APS (DK) | 2026-05-15 | — | — | WO | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-4150053-A | 2-Decarboxy-2-aminomethyl-6-hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1979-04-17 | — | — | US | claimed |
| US-4147877-A | ω-aryl-6-hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1979-04-03 | — | — | US | claimed |
| US-4145535-A | Pyran analogs of trans-4,5-didehydro-PGI compounds | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | claimed |
| US-4136095-A | ANTICOAGULATNS, HYPOTENSIVE AGENTS, ANTIHISTAMINES, DECONGESTANTS | THE UPJOHN COMPANY (US) | 1979-01-23 | — | — | US | claimed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | claimed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | claimed |
| US-4110532-A | PROSTAGLANDINS, SMOOTH MUSCLE STIMULANTS | THE UPJOHN COMPANY (US) | 1978-08-29 | — | — | US | claimed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | claimed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | claimed |